Table 2:

Composite endpoints: time to CV death or HF event and time to all-cause death or HF event.

Outcome	Empagliflozin (n=265)	Placebo (n=265)	Hazard Ratio	(95% CI)
CV death or HF Event	34	49	0.69	(0.45, 1.08)
All-cause death or HF Event	37	57	0.65	(0.43, 0.99)
CV death	8	14
All-cause death	11	22
≥1 HF event	28	39
Total HF events	36	52

Table 2 shows the results of time to first event analyses for the composite outcomes of (i) CV death or HF event and (ii) all cause death or heart failure event. We see that the composite ignores 6 cardiovascular deaths (which occurred after a HF event) and 21 repeat HF events. In contrast, the win ratio analysis incorporates all this information. HFE = heart failure event; CV = cardiovascular; CI = confidence interval.